Comparative Pharmacology
Head-to-head clinical analysis: CARBATROL versus PHENURONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARBATROL versus PHENURONE.
CARBATROL vs PHENURONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stabilizes neuronal membranes by blocking voltage-gated sodium channels, inhibiting repetitive firing of action potentials. Also enhances GABAergic activity.
Phenurone (phenacemide) is an anticonvulsant that reduces neuronal excitability by inhibiting voltage-gated sodium channels and potentiating GABAergic inhibition. It also has a structure similar to other hydantoins and may increase the seizure threshold.
Initial dose 200 mg orally twice daily, increase by 200 mg/day at weekly intervals; maintenance 800-1200 mg/day in 2 divided doses extended-release capsules.
Adults: 500 mg to 1 g orally twice daily, increased gradually up to 3 g/day in divided doses.
None Documented
None Documented
Terminal elimination half-life 25-65 hours initially, then 12-17 hours after autoinduction; clinical context: requires dose adjustment after 3-5 weeks.
The terminal elimination half-life is approximately 22-35 hours in adults. This long half-life supports once- or twice-daily dosing, but requires careful monitoring for accumulation.
Renal: 70% as metabolites (including carbamazepine-10,11-epoxide) and 2-3% as unchanged drug; biliary/fecal: 30%.
Phenurone is extensively metabolized in the liver; less than 1% is excreted unchanged in urine. The primary metabolite is 4-hydroxyphenylethylhydantoin (p-HPEH). Renal excretion accounts for approximately 70-80% of the dose, mainly as metabolites; the remainder is eliminated via bile/feces. Enterohepatic circulation may occur.
Category C
Category C
Anticonvulsant
Anticonvulsant